New Delhi: Drug major Cipla on Thursday revealed the commercialisation of its RT-PCR test set 'ViraGen' for COVID-19 in India, in collaboration with Ubio Biotechnology Systems.
This launch will help address the present testing services and capability problems while reaffirming the business's continuous growth in the diagnostic area, Cipla said in a regulatory filing.
Cipla will release ViraGen test kit in the country in collaboration with Ubio Biotechnology Systems, the business stated.The company will commence supply of the COVID-19 infection detection kit from May 25, 2021.
Umang Vohra, MD and Worldwide CEO, Cipla, stated, Cipla has been working relentlessly to ensure accessibility to treatments in this fight against COVID-19.
Guided by our core function of 'Taking care of Life', this partnership will allow us to reach out to more people throughout the nation at a vital time like now .
ViraGen is Cipla's third offering in the COVID-19 testing section.